BioCentury
ARTICLE | Financial News

Third Rock funnels $58.5M into autophagy newco Casma

May 3, 2018 10:05 AM UTC

Casma Therapeutics Inc. (Cambridge, Mass.) debuted on Thursday with a tranched $58.5 million series A round from Third Rock Ventures (see BioCentury, May 3).

Casma’s therapeutics induce autophagy to treat inflammatory, neurodegenerative, muscular and lysosomal storage diseases. ...

BCIQ Company Profiles

Third Rock Ventures